Iovance Biotherapeutics announced that lifileucel, a one-time TIL cell therapy, achieved a 50% confirmed objective response rate in a pilot trial for advanced soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The responses were durable, ongoing for up to 46+ weeks, in patients with heavy disease burden and refractory to prior treatments. This marks a significant advancement as current second-line treatments show much lower response rates and survival outcomes. The FDA granted fast track designation for lifileucel, and Iovance is enrolling patients in the SARATOGA Phase 2 trial to support further approvals.
Iovance Biotherapeutics shares are trading at USD 14.25 on Pluang as of Oct 26, 2026 18:11 WIB. The stock has seen a modest 1.14% increase in the last day. Its market capitalization stands at $6.38 billion, reflecting steady investor interest in the health sector.
